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Keywords:
to improve the therapeutic possibilities is to investigate the kinetics of
the parent compound isoniazid, responsible for the therapeutic effect
and for the adverse effect as well, and its main acetylated metabolite
acetylisoniazid (ac-INH).
It is well known that the liver of newborns is immature and that
maturation of the liver takes years. Therefore, investigating the acetyla-N-acetyltransferase 2
Tuberculosis
Isoniazid
ChildrenTuberculosis is an infectious disease which can be treated better
when the applied dose of the anti-tuberculosis drug is optimal. The
basic antituberculosis drug isoniazid (INH) was one of the ﬁrst medical
drugs for which individual differences in themetabolismwere reported
more than 50 years ago (Jenne, 1960). Later it was shown that the poly-
morphic xenobiotic metabolizing enzymeN-acetyltransferase 2 (NAT2)
was responsible for the observed metabolic differences which were as-
sociated with different serum or urine levels of the parent compound
and its main metabolites. In a meta-analysis of 13 randomized studies
in adults, fast acetylators had higher rates of therapy failure and
acquired drug resistance than slow acetylators (Pasipanodya et al.,
2012). The observed metabolic differences are also associated with dif-
ferent adverse drug effects. Slow acetylators were reported to present
more hepatotoxicity and more peripheral neurotoxicity (Preziosi,
2007). A large meta-analysis of 26 studies, mostly from East Asia,
showed that adult slow acetylators have a signiﬁcantly higher risk (OR
3.10, 95% CI 2.47–3.88) for antituberculosis drug-induced hepatotoxici-
ty (Du et al., 2013).
The most common adverse effect of INH therapy is liver toxicity. In
adults, up to 20% of the treated patients show increased alanine
aminotransaminase levels and overt liver toxicity may occur in up to
2% of the patients (Hassan et al., 2015). More important is the fact that
serious liver damage may also occur. In some cases the liver damage
can only be treated by a very sophisticated therapy like temporary use
of an artiﬁcial liver or, as ultima ratio, by liver transplantation (Li et al.,
2015).
Compared to the situation of physicians in adult medicine, pediatri-
cians have clearly less information for an optimal dose of the antituber-om.2016.07.031.
hysiologie und Arbeitschutz e.V. Puculosis drug INH. From the pharmacological point of view, the ﬁrst step
tion capacity of NAT2with regards to the known speciﬁc liver toxicity of
INH is warranted.
The paper of Rogers et al. (2016) is aﬁrst step to enhance this knowl-
edge concerning the reaction kinetics of INH and ac-INH in children. The
authors describe an age of about 5.3 years when the non-linear modiﬁ-
cation of the contribution of the NAT2 genotype to the INH metabolism
ends.
The applied non-parametric regression approach multivariate adap-
tive regression splines (MARS) is a sophisticated extension of the linear
regressionmodel using functions (so-called basic functions) of the inﬂu-
ence factors (or independent variables) instead of the variables them-
selves. It is particularly designed to model non-linear effects as well as
their interaction which are both of special interest in this study. MARS
includes variable selection to obtain a good ﬁt of the model with a min-
imum set of most relevant inﬂuence factors. Cross validation is used to
assuremodel validity. One advantage of MARS is the good interpretabil-
ity of the results allowing for the above described conclusion of Rogers
et al. (2016): an age of 5.3 years is a change point for NAT2modulation
of INH metabolism.
During this decade, ultra-slow NAT2 have entered the stage (Ruiz et
al., 2012, Selinski et al., 2013, 2015). Slow acetylators in general have a
lower metabolic capacity, compared to rapid acetylators. It is remark-
able that ultra-slow acetylators have about 30–40% decreasedmetabolic
capacity, compared to all other slow NAT2 genotypes (Ruiz et al., 2012,
Selinski et al., 2013). It will be very interesting to ﬁnd out whether the
ultra-slow acetylation status has a detectable impact on INH metabo-
lism in children and in adults as well – and whether the age of the ma-
tured liver will change.
For the clinician, it is important to note that the child's height and
age, and not the body weight which is often used to adapt the dose in
young children, are the most important predictors for liver maturation.
The authors conclude that at 5.3 years maturation of the liver in the
South African children of African descent is complete. It demands fur-
ther research whether this age is also applicable to children of Asian
or Caucasian descent where the distribution of the NAT2 haplotypes is
different and, even more importantly, whether this age is relevant also
for the application of other medical drugs or not. Particularly the latterblished by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
12 K. Golka, S. Selinski / EBioMedicine 11 (2016) 11–12is an unexplained pediatric space (Kearns et al., 2003) which is of
utmost clinical and theoretical relevance.
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